...salient points...I have only been in for about 10 months for the same story...I suppose I cling to the notion that some westernization may still take place in pharma-retail over there, specifically with prescription medication, which could be a catalyst...
Agenus Inc And GlaxoSmithKline's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Agenus Inc announced that GlaxoSmithKline`s DERMAi study, a Phase 3 randomized,
blinded, placebo-controlled MAGE-A3 cancer immunotherapeuticii (CI) trial, which
contains Agenus`QS-21 Stimulon adjuvantiii, a component of GSK`s novel adjuvant
system AS15, did not meet its first co-primary endpoint. In an independent
analysis, the study did not significantly extend the disease-free survival
(DFS)iv period when compared to placebo in the overall MAGE-A3 positive trial
population. In line with the Independent Data Monitoring Committee`s (IDMC)
unanimous recommendation, GSK will continue the study until the second
co-primary endpoint is assessed. This co-primary endpoint is based on predefined
criterion that was agreed upon by regulatory authorities. This analysis, which
is based on gene signature, is designed to prospectively identify patients who
may have the capability to be more immunologically responsive and therefore can
potentially benefit from treatment. If further analysis shows that the
predefined gene signature subset data are successful, there is the potential
that a regulatory filing could be considered. GSK anticipates that these data
will be available in 2015. Until then, GSK will remain blinded to all safety and
efficacy data. The IDMC for the DERMA study indicated that the current review of
the safety information raised no concern for the continuation of the trial.
Geez: Let them come out with their upcoming interim data first---then we can parse whether they get to submit, whether there will be a REMS with any approval, or whether there will be an advisory meeting to hash it all out? Or even if the data suggests carrying on the study without submitting at this point---that is possible. The FDA will decide this in the end via conversations with OREX! As SP says its all a guess at this point!
The markets know attaching to VVUS was a mistake, they still aren;t buyng totally into Belviq off their perceived LOE (not much true), so OREX is Mr markets latest hero to attach to like a bloodsucker! They may be repeating their VVUS mistake on the next combi coming down the pike?
I wait until data comes out! Then maybe the markets will go whoa if said data isn;t compelling! I will continue to have cardio concerns about this combi plus other AE issues until they PROVE its unwarrented. I see little way this drug could even be on the market selling until 2015 myself off the likely process it needs to go thru.
Lets wait and see!
Sentiment: Strong Buy
You should consider owning both stocks! Bio-Diversification is good!
Sentiment: Strong Buy
Fannie Mae Preparing For First Transaction Where Bond Investors Share Mortgage Default Risk
Anthony B. Sanders – George Mason University
September 4, 2013
Please Google to find the article. Fannie Mae is planning to survive, no matter which changes the government may throw at them.
Z-wave look to be the best play on the "connectivity of little things". Maybe an even bigger cloud biz than just the internet of things? We don't get detailed figures, but the 0.6 m sequential increase in sales "mainly" attributed to z-wave would suggest 60% annualized growth... or maybe to 20 m/year at the end of this year.
20 million devices using z-wave... well, sold anyway! Maybe Siggie should ipo this bit? it is not that dependent on the other businesses. A 200m-valued ipo would be one way to jump-start shareholder value creation here!
Wall Street hottest stock is currently Envivio (ENVI), which gained 6.5% on Tuesday, 6% on Wednesday and 29% afterhours on Wednesday after reporting fiscal 2Q 2014 revenues of $11.548 million and a net loss of ($2.48 million) or ($0.09) per share. Compared to fiscal 2Q 2013, ENVI grew revenues by 7% while reducing its net loss by 42%. ENVI has 27.6mm shares outstanding and finished afterhours trading at $3.60 with a market cap of $99.36mm. After subtracting ENVI's cash position of $52.563mm, ENVI has an enterprise value at $3.60 of $46.797mm. With trailing 12 mo revenues of $33.934mm, ENVI has an enterprise value/revenue ratio at $3.60 of 1.38.
ENVI's multi-screen video delivery business is receiving huge orders from two Tier 1 U.S. pay-TV operators, one of them being Time Warner Cable (TWC). However, despite ENVI rising 49% during the past week, it has now posted 6 straight quarterly net losses. If you are looking for the next stock in this tech space to rise 49% within a week - look at Concurrent (CCUR), which just reported their 6th straight quarterly net profit. Over the past 5 quarters, CCUR has grown its EPS from $0.02, to $0.04, to $0.08, to $0.11, and to $0.26.
CCUR will file its 10-K any day now and just like ENVI, CCUR will report huge order increases from two Tier 1 U.S. pay-TV operator clients, one of them being TWC - who is using the technology of both ENVI and CCUR for multi-screen video delivery. CCUR's 10-K will likely show record annual free cash flow of over $6.2mm vs. ENVI's latest trailing free cash flow of negative ($20mm). CCUR is the biggest gem on Wall Street and at its current price of $7.86, CCUR has an enterprise value/revenue ratio of only 0.64!
To match ENVI's multiple of 1.38, CCUR needs to rise 68% to $13.19 per share, which could happen very quickly! If you own CCUR at the close of trading on Wednesday of next week you will receive a huge $0.12 per share cash dividend payment! CCUR just doubled its dividend and pays a 6.1% yield!
...just think carmi, that's only about 30 lawns to mow for you to earn the money? 40? that, along with your weekly allowance and you can pay for all 3 of them! i imagine one of your "lucky" relatives or special friends will be getting one for Christmas from you! lol, hug from italy. LOOOOOOOL!
this certainly fits.. google this and read the zerohedge piece:::"""Is The US Going To War With Syria Over A Natural Gas Pipeline?"""""
...and this coming from the Nobel PEACE prize winner (obama) and PEACE activist? (sheehan); no wonder the rest of the world is confused, even Putin pointed out that hypocrazy. then again, both are communists and not really representative of most americans.
"From this seat ..."
It's "From where I sit...".
"Tell the folks about the bad news headed!!"
India? China? Which is it?
My money is on India, your name is Sanjay, your girlfriend is Priya, and you live with your parents, grandparents, two brothers, and a goat just outside of Delhi.
How's the weather in Delhi today Sanjay?